MIRAE ASSET SECURITIES Buys Back 300 Billion Won Worth of Treasury Stock… Largest Ever
Aimed at Enhancing Shareholder Value and Narrowing the Market Price Discrepancy of Preferred Shares
Three times the size of the largest acquisition to date
Simultaneous Purchase of Common and Preferred Stock… First Acquisition of 1 Preferred Share
Plans to Cancel All Shares Following Acquisition
[Edaily Reporter Hyera Lee ] MIRAE ASSET SECURITIES(006800)is acquiring 300 billion won worth of its own shares. The move is aimed at revaluing the stock price and enhancing shareholder value. Citizens walk past the Mirae Asset headquarters in Jung-gu, Seoul, on the 15th. (Photo by Reporter Lee Young-hoon) MIRAE ASSET SECURITIES announced on the 17th that its board of directors, at a meeting held that day, resolved to repurchase 300 billion won worth of its own shares. This acquisition marks the largest in the company’s history, amounting to approximately three times the previous record of 103 billion won. Specifically, the purchase will consist of 200 billion won worth of common stock, 10 billion won worth of Class 1 preferred stock, and 90 billion won worth of Class 2 preferred stock. This is the first time Class 1 preferred stock has been included in the purchase. This decision was made to narrow the price gap between common and preferred stock and to enhance shareholder value in a balanced manner. MIRAE ASSET SECURITIES has consistently implemented its shareholder return policy by purchasing and subsequently canceling its own shares. The company plans to cancel all of the shares acquired in this round immediately after purchase. A MIRAE ASSET SECURITIES official stated, “This share repurchase was decided to enhance shareholder value, stabilize the stock price, and narrow the market price gap between common and preferred shares,” adding, “We plan to faithfully implement our shareholder return policy by repurchasing and canceling the shares.”
ABLE C&C(078520)is establishing a subsidiary in the Netherlands to serve as the control tower for its European operations. Following the establishment of its UK subsidiary, the company is setting up a…
On the afternoon of the 18th, at the Vuori pop-up store in Seongsu-dong, Seongdong-gu, Seoul, a different scene unfolded as I passed through the first and second floors—where clothes were displayed—an…
As global Big Pharma companies embark on large-scale mergers and acquisitions (M&A) to overcome the patent cliff and growth limitations, there are increasing instances of Chinese biotech companies bei…